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Abstract
 
Infections with gram-positive bacteria are a major cause of morbidity and mortality in humans.
Opsonin-dependent phagocytosis plays a major role in protection against and recovery from
gram-positive infections. Inborn and acquired defects in opsonin generation and/or recognition
by phagocytes are associated with an increased susceptibility to bacterial infections. In contrast,
the physiological significance of opsonin-independent phagocytosis is unknown. Type I and II
class A scavenger receptors (SR-AI/II) recognize a variety of polyanions including bacterial cell
wall products such as lipopolysaccharide (LPS) and lipoteichoic acid (LTA), suggesting a role
for SR-AI/II in innate immunity to bacterial infections. Here, we show that SR-AI/II–defi-
cient mice (MSR-A
 
2
 
/
 
2
 
) are more susceptible to intraperitoneal infection with a prototypic
gram-positive pathogen, 
 
Staphylococcus aureus
 
, than MSR-A
 
1
 
/
 
1
 
 control mice. MSR-A
 
2
 
/
 
2
 
 mice
display an impaired ability to clear bacteria from the site of infection despite normal killing of
 
S
 
.
 
 aureus
 
 by neutrophils and die as a result of disseminated infection. Opsonin-independent
phagocytosis of gram-positive bacteria by MSR-A
 
2
 
/
 
2
 
 macrophages is significantly decreased al-
though their phagocytic machinery is intact. Peritoneal macrophages from control mice phago-
cytose a variety of gram-positive bacteria in an SR-AI/II–dependent manner. Our findings
demonstrate that SR-AI/II mediate opsonin-independent phagocytosis of gram-positive bacte-
ria, and provide the first evidence that opsonin-independent phagocytosis plays a critical role in host
defense against bacterial infections in vivo.
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Staphylococcus aureus
 
Introduction
 
Phagocytosis of microorganisms is a key element in host
defense against bacterial infections (1). Two principal mech-
anisms of phagocytosis have been described, opsonin-depen-
dent phagocytosis (2) and opsonin-independent phagocy-
tosis (for a review, see reference 3). In opsonin-dependent
phagocytosis, immunoglobulin or complement molecules
bind to microorganisms, thereby promoting ingestion via
Fc
 
g
 
 or complement receptors on phagocytic leukocytes (2).
In contrast, in opsonin-independent phagocytosis, ligands
on the surfaces of microorganisms are directly recognized
by receptors on the plasma membranes of phagocytes (3).
Several lines of evidence link defects in opsonin-depen-
dent phagocytosis to an increased susceptibility to infec-
tion. First, immunoglobulin- or complement-deficient ani-
mals (4–6) and humans (7) exhibit an increased incidence
of bacterial infections. Second, administration of antibodies
against bacterial capsular antigens (8–10), or immunization
against bacterial capsular antigens (11), protects against in-
fections with bacteria expressing these antigens. Third, Fc
 
g
 
receptor polymorphisms in humans (12, 13) are associated
with increased susceptibility to infection.
Much less is known about the physiological roles of op-
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sonin-independent phagocytosis in host defense against bac-
terial infections. Types I and II class A macrophage scavenger
receptors (SR-AI/II)
 
1
 
 are homotrimeric membrane proteins
(14) of mononuclear phagocytes that mediate phagocytosis
of apoptotic thymocytes (15), endocytosis of modified lipo-
proteins (16), and adhesion of macrophages to surfaces
coated with serum proteins (17), glucose-modified basement
membrane proteins (18), and 
 
b
 
-amyloid fibrils (19). The
demonstration that macrophage scavenger receptors bind
bacterial cell wall components such as LPS from gram-neg-
ative bacteria (20) or lipoteichoic acid (LTA) from gram-
positive bacteria (21), and that SR-AI/II–deficient mice
(MSR-A
 
2
 
/
 
2
 
) exhibit increased susceptibility to infection
with 
 
Listeria monocytogenes
 
 (22) and to LPS-mediated shock
(23) suggested that these receptors function in the absence of
serum opsonins in host defense against bacterial infections.
We hypothesized that SR-AI/II mediate opsonin-inde-
pendent phagocytosis of bacteria via a direct interaction of
SR-AI/II with bacterial cell wall products such as LTA,
leading to clearance of bacteria from sites of infection. To
test this hypothesis, we chose 
 
Staphylococcus aureus
 
, a proto-
typical gram-positive microorganism and an important cause
of life-threatening bacterial infections in humans (24–26).
Since SR-AI/II are expressed mainly on mononuclear
phagocytes, and these cells are the first line of antimicrobial
defense in the peritoneal cavity (27–29), we compared the
susceptibility of MSR-A
 
2
 
/
 
2
 
 and MSR-A
 
1
 
/
 
1
 
 mice to intra-
peritoneal challenge with two strains of 
 
S
 
.
 
 aureus
 
. Here, we
show that intraperitoneal injection of 
 
S
 
.
 
 aureus
 
 Cowan strain I
leads to overwhelming infection and death in MSR-A
 
2
 
/
 
2
 
mice at a significantly lower dose than in wild-type mice. The
impaired ability of MSR-A
 
2
 
/
 
2
 
 mice to clear 
 
S
 
.
 
 aureus
 
 from
the peritoneal cavity is associated with a marked decrease in
the ability of their peritoneal macrophages to phagocytose
nonopsonized 
 
S
 
.
 
 aureus
 
 as well as several other gram-positive
bacteria. This is the first direct evidence that opsonin-inde-
pendent phagocytosis of bacteria is a critical determinant of
host survival in bacterial infection.
 
Materials and Methods
 
Mice and Bacteria.
 
SR-AI/II knockout mice (MSR-A
 
2
 
/
 
2
 
) are
described in detail elsewhere (22). MSR-A
 
2
 
/
 
2
 
 or BALB/c con-
trol mice (The Jackson Laboratory) were kept in a germ-free bar-
rier facility with free access to autoclaved water and irradiated
Purina-Pico mouse diet (W.F. Fisher & Son, Inc.). 
 
S. aureus
 
(Wood strain, 10832), 
 
S. aureus
 
 (Cowan I strain, 12598), 
 
S. aureus
 
(Smith diffuse strain, 13709), 
 
Streptococcus agalactiae
 
 (12386), 
 
Strep-
tococcus pyogenes
 
 (10403), 
 
L. monocytogenes
 
 (43251), and 
 
Enterococcus
hirae
 
 (9790) were from the American Type Culture Collection.
 
S. aureus
 
 (strain DB) was a gift from Dr. A. Cheung, Rockefeller
University, New York, NY. Heat-inactivated, BODIPY
 
® 
 
fluo-
rophore–labeled 
 
S
 
.
 
 aureus
 
 (Wood strain) and zymosan particles
were from Molecular Probes.
 
Infection Assay. S
 
.
 
 aureus
 
 (Cowan I) was grown overnight in
Brain Heart broth (Difco) in a bacterial shaker at 37
 
8
 
C. On the
day of an experiment, bacteria were washed three times in phos-
phate-buffered saline (PD) without Ca
 
2
 
1
 
/Mg
 
2
 
1
 
 and spectropho-
tometrically adjusted to OD 
 
<
 
 
 
2.0 (10
 
8
 
 CFU/ml). The number
of viable bacteria was confirmed by plating serial dilutions on
Brain Heart agar plates and counting bacterial colonies after over-
night incubation at 37
 
8
 
C. For each experiment, four MSR-A
 
2
 
/
 
2
 
or four MSR-A
 
1
 
/
 
1
 
 control mice (4–6 wk of age, 20–25 g) were
injected intraperitoneally with 1 ml PD containing 2 
 
3 
 
10
 
7
 
–10
 
9
 
CFU of the indicated microorganism and observed for 72 h.
Moribund animals were killed with CO
 
2
 
. At various time points
after injection, mice were killed and blood and peritoneal fluid
were harvested and assayed for the presence of viable bacteria by
plating serial dilutions on agar plates. Blood was obtained by car-
diac puncture. Three to six experiments of this type were per-
formed, as indicated in the figure legends.
 
Analysis of Peritoneal Cells of Mice Inoculated Intraperitoneally with
S. aureus.
 
The total number of white blood cells in the peritoneal
fluid was determined using a hemocytometer. Leukocytes were
typed by evaluating a Wright’s stained smear of peritoneal fluid.
 
Killing of S. aureus by Peritoneal Neutrophils In Vitro.
 
Neutrophil
bactericidal activity was assayed in a modified tumble assay (30).
In brief, MSR-A
 
1
 
/
 
1
 
 control mice or MSR-A
 
2
 
/
 
2
 
 mice were in-
oculated intraperitoneally with 1 ml of 2% sodium caseinate
(Sigma Chemical Co.) (31), and the resulting neutrophil-rich ex-
udate was harvested 6 h later by lavage as described above. The
exudate cells (75% neutrophils) were washed, counted, and sus-
pended at a concentration of 2.6 
 
3
 
 10
 
6
 
 exudate cells/ml in PBS
(with Ca
 
2
 
1
 
 and Mg
 
2
 
1
 
) containing 0.1% human serum albumin
and 5 mM glucose. 
 
S
 
.
 
 aureus 
 
(Cowan I) was grown overnight,
washed, suspended at a concentration of 2 
 
3
 
 10
 
5
 
 CFU/ml in
PBS containing 0.9 mM Ca
 
2
 
1
 
 and 0.5 mM Mg
 
2
 
1
 
, 5 mM glucose,
0.1% human serum albumin, and 20% mouse serum (as a source
of complement; Sigma Chemical Co.), and incubated for 10 min
at 37
 
8
 
C to opsonize the bacteria. 250 
 
m
 
l aliquots of this bacterial
suspension were mixed with 250 
 
m
 
l of the neutrophil suspension,
and the mixture was incubated at 37
 
8
 
C for 1 h on a rotary shaker.
The mixture was then diluted sixfold in sterile distilled water, in-
cubated for 5 min to lyse the neutrophils, and the number of
CFU of 
 
S
 
.
 
 aureus
 
 was determined by plating serial dilutions on
agar plates. Data are reported as percent reduction in CFU of
 
S
 
.
 
 aureus 
 
incubated with neutrophils, and were calculated as
1 
 
2
 
 no. of CFU recovered at 1 h/no. of CFU in the inoculum at
time 0 (i.e., 1 
 
3
 
 10
 
5
 
 CFU). In the absence of neutrophils, the
number of CFU of 
 
S
 
.
 
 aureus 
 
increased by 1.5-fold over 1 h. No
 
S
 
.
 
 aureus
 
 killing occurred when neutrophils and bacteria were in-
cubated in medium containing mouse serum lacking complement
activity.
 
Fluorescent Labeling of Bacteria.
 
Bacteria were labeled with
BODIPY
 
® 
 
FL (Molecular Probes) according to the manufacturer’s
specifications. Bacteria were grown overnight in 5–10 ml Brain
Heart broth, washed twice, and resuspended in 0.2 ml buffer (0.1 M
NaHCO
 
3
 
, 125 mM NaCl). 100 
 
m
 
g BODIPY
 
® 
 
FL was added
slowly, and bacteria were incubated under constant stirring in the
dark at room temperature for 1 h. The reaction was stopped by
dropwise addition of 1.5 M hydroxylamine (Sigma Chemical
Co.). Bacteria were washed and resuspended in PD at OD
 
 5 
 
2.0
(
 
<
 
10
 
8
 
 CFU/ml). Bacterial viability was checked by plating serial
dilutions and was typically 
 
.
 
80%.
 
Phagocytosis of Bacteria by Macrophages In Vitro.
 
Thioglycollate
broth–elicited peritoneal macrophages (TMf) were harvested by
irrigating the peritoneal cavity of mice with cold PD 4 d after in-
1Abbreviations used in this paper: LTA, lipoteichoic acid; MSR-A2/2 mice,
macrophage scavenger receptor–deficient mice; MSR-A1/1 mice, wild-
type mice; SR-AI/II, type I and/or II class A macrophage scavenger re-
ceptors; TMf, thioglycollate broth–elicited peritoneal macrophage(s).149 Thomas et al.
traperitoneal injection of 2 ml aged thioglycollate broth (Sigma
Chemical Co.). TMf were plated in 96-well plates at 105 cells/
well in 100 ml RPMI 1640/10% fetal calf serum and incubated
overnight. TMf were washed once with PD, and labeled bacte-
ria were added at <100 CFU/macrophage for 30 min at 378C.
Phagocytosis was stopped by addition of cold PD. Fluorescence
of extracellular bacteria was quenched by incubation with PD
containing 1.0 mg/ml trypan blue for 20 min at room tempera-
ture as described (32, 33). Intracellular fluorescence of phagocy-
tosed bacteria was measured at l 5 485 nm (excitation) and l 5
530 (emission), using a fluorescence plate reader (Cytofluor II;
PerSeptive Biosystems). To determine background fluorescence
from noningested extracellular bacteria, TMf were incubated
with 1.0 mM cytochalasin D (Sigma Chemical Co.) to inhibit
phagocytosis, and fluorescence was measured after trypan blue
quenching (32–34). Phagocytosis is expressed as the ratio of fluo-
rescence of phagocytosed bacteria to fluorescence of adherent but
uningested bacteria: a value of 1 is equal to background fluores-
cence; values .1.0 indicate the presence of intracellular (phago-
cytosed) bacteria. Results were confirmed by fluorescence micros-
copy. In some experiments, TMf were preincubated for 30 min (at
room temperature) with the antibodies 2F8 (Serotec) or EM-34.1
(Sigma Chemical Co.), or 500 mg/ml of one of the following
SR-AI/II ligands: polyinosinic acid, polyguanylic acid, fucoidan,
or LTA, or the control reagent polycytidylic acid in the presence
of a ribonuclease inhibitor (all from Sigma Chemical Co.).
Results
Decreased Clearance of S. aureus by MSR-A2/2 Mice.
MSR-A1/1 and MSR-A2/2 mice were injected intraperi-
toneally with 107 CFU S. aureus Cowan I, and viable bac-
teria were quantified in blood and peritoneal lavage samples
at the indicated time points. The number of viable bacteria
recovered from the peritoneum of MSR-A1/1 mice de-
creased to z0.01% of the inoculum and to ,0.3% of the
number of bacteria recovered from the peritoneum imme-
diately after infection (i.e., from 4.0 3 105 to 1.1 3 103
CFU/mouse) within 24 h (Fig. 1 A). No bacteria were de-
tected in the blood of MSR-A1/1 mice by 12 h (Fig. 1 B).
In contrast, the number of viable bacteria in the perito-
neum of MSR-A2/2 mice was 20% of the inoculum at
24 h (Fig. 1 A) and increased 200-fold in the blood at 12 h
compared with 5 min after inoculation (Fig. 1 B).
Decreased Survival of MSR-A2/2 Mice after Infection with
S. aureus. Impaired ability to eliminate S. aureus may lead
to increased mortality from disseminated infection. To test
this, we injected MSR-A2/2 and MSR-A1/1 mice with
increasing numbers of S. aureus. All control mice survived
intraperitoneal infection with 2 3 107 and 2 3 108 CFU of
S. aureus, whereas 40 and 60% of MSR-A2/2 mice became
moribund within 24 h (Fig. 2, A and B) after inoculation
with 2 3 107 and 2 3 108 CFU of S. aureus, respectively.
20% of control mice became moribund within 24 h of in-
fection with 109 CFU/mouse (Fig. 2 C). In contrast, 90%
of MSR-A2/2 mice became moribund within 12 h of in-
fection with 109 CFU of S. aureus (Fig. 2 C). No further
deaths were observed in either group after 48 h. Thus, tar-
geted disruption of the SR-AI/II gene significantly increased
the susceptibility of mice to infection with S. aureus.
Normal Recruitment of Inflammatory Cells by MSR-A2/2
Mice after Infection with S. aureus. Atherosclerotic lesions in
MSR-A2/2 mice contain significantly fewer macrophages
compared with lesions in MSR-A1/1 mice (22). To exam-
ine whether the increased susceptibility of MSR-A2/2 mice
to S. aureus reflected a similar defect in recruitment of mac-
rophages or other leukocytes to the site of infection, peri-
toneal cells from MSR-A2/2 and MSR-A1/1 mice were
harvested at various times after intraperitoneal injection of
S. aureus. Before infection, the peritoneal cavities of MSR-
A2/2 and MSR-A1/1 mice contained similar numbers of
resident peritoneal cells, .99% of which were mononu-
clear leukocytes, and the majority of which were mononu-
clear phagocytes (not shown). As described previously (27),
intraperitoneal injection of S. aureus induced a marked in-
flux of leukocytes, .99% of which were neutrophils (Fig.
3). There were no significant differences between MSR-
A2/2 and MSR-A1/1 mice in either the number or types of
leukocytes that were recovered from the peritoneal cavity
after intraperitoneal injection of S. aureus (Fig. 3). Thus, the
increased susceptibility of MSR-A2/2 mice to S. aureus in-
fection cannot be explained by lack of recruitment of neu-
trophils or mononuclear phagocytes to the peritoneal cavity.
SR-AI/II Mediate Opsonin-independent Phagocytosis of Gram-
positive Bacteria. SR-AI/II bind LPS from gram-negative
bacteria (20), LTA and gram-positive bacteria (21), and pos-
sibly Mycobacterium tuberculosis (35) to macrophages. We hy-
pothesized that SR-AI/II play an important role in host
defense against intraperitoneal infection with S. aureus by
mediating opsonin-independent phagocytosis of this bacte-
Figure 1. Clearance of S. aureus by MSR-
A2/2 and MSR-A1/1 mice. 107 CFU S. au-
reus (Cowan I) were injected into the peri-
toneal cavity of four MSR-A2/2 and four
MSR-A1/1 mice. (A) At the indicated
times, the peritoneum was lavaged and its
content of viable bacteria was determined by
plating serial dilutions on agar plates. (B) Vi-
able bacteria in the blood were determined
after collecting blood via cardiac puncture of
killed animals and subsequent plating on
agar plates at the indicated times. Data rep-
resent the mean of three experiments.150 Macrophage Scavenger–dependent Phagocytosis in Gram-positive Infection
rium. To test this, we compared phagocytosis of four strains
of S. aureus, as well as of three other gram-positive micro-
organisms, by TMf from MSR-A2/2 and MSR-A1/1
mice. All gram-positive bacteria, with the exception of an
encapsulated S. aureus strain (Smith diffuse), were efficiently
ingested by TMf from MSR-A1/1 mice in the absence of
added opsonins (Fig. 4 A). TMf from MSR-A2/2 mice
phagocytosed 72–83% fewer bacteria than TMf from
MSR-A1/1 mice (Fig. 4 A). In contrast, zymosan, a parti-
cle whose uptake is mediated by mannose and b-glucan
receptors (36), was phagocytosed with equal efficiency
by TMf from MSR-A2/2 and MSR-A1/1 mice, indicat-
ing that macrophages from MSR-A2/2 mice possess intact
phagocytic machinery.
Macrophages have been shown to secrete sufficient
complement to opsonize zymosan for phagocytosis (37).
To test the possibility that complement receptors or other
membrane integrins played a role in phagocytosis of gram-
positive bacteria, we compared phagocytosis of gram-posi-
tive bacteria by incubating TMf from MSR-A2/2 and
MSR-A1/1 mice in medium with and without Ca21 and
Mg21. Ca21 and Mg21 are required for complement activa-
tion and for most integrin-mediated functions, but not for
interactions of SR-AI/II with their ligands (14, 17–19).
TMf from MSR-A2/2 and MSR-A1/1 mice ingested 62–
95% as many organisms in Ca21/Mg21-free medium (Fig.
4 B) as in Ca21/Mg21-containing medium, demonstrating
that the phagocytosis of these bacteria was both comple-
ment independent and integrin independent.
LTA, a major cell wall component of gram-positive bac-
teria (38) and a known ligand of SR-AI/II (21), inhibited
opsonin-independent phagocytosis of S. aureus and other
gram-positive bacteria (Fig. 4, C and E), suggesting that
soluble LTA was competing with LTA on the surfaces of
these bacteria for receptors on the macrophage plasma mem-
brane. In addition to LTA, phagocytosis of S. aureus was
inhibited by other SR-AI/II ligands (polyinosinic acid,
polyguanylic acid, fucoidan), whereas a control reagent (poly-
cytidylic acid) that does not block SR-AI/II receptors had
no effect (Fig. 4 C). Furthermore, 2F8, an mAb that specif-
ically recognizes murine SR-AI/II (17) and that has been
shown to block SR-AI/II–mediated phagocytosis of apop-
totic thymocytes (15), inhibited phagocytosis of three dif-
ferent strains of S. aureus and of E. hirae and B. subtilis by
56–95% (Fig. 4 D). An isotype-matched control antibody
(EM-34.1) had no effect (Fig. 4 D). In contrast, phagocytosis
of unopsonized zymosan was unaffected by 2F8 (Fig. 4 C).
Both 2F8 and LTA inhibited S. aureus phagocytosis by TMf
from wild-type mice in a dose-dependent manner (Fig. 4 E).
Interestingly, LTA inhibited S. aureus phagocytosis to a greater
extent than 2F8 (Fig. 4 E). This was similar to a previous
report that 2F8 incompletely blocks phagocytosis of apop-
Figure 2. Mortality of MSR-A2/2 and MSR-A1/1 mice after S. aureus
challenge. Four MSR-A2/2 and four MSR-A1/1 mice were injected
intraperitoneally with 1 ml of buffer containing S. aureus (Cowan I): (A)
2 3 107 CFU, (B) 2 3 108 CFU, (C) 109 CFU. Mice were observed for
signs of systemic infection, and moribund animals were killed. Data rep-
resent the mean of six experiments.
Figure 3. Recruitment of peritoneal leu-
kocytes. Four MSR-A2/2 mice and four
MSR-A1/1 mice were injected intraperito-
neally with 107 CFU of S. aureus (Cowan I).
At the indicated times, mice were killed and
their peritoneal cavities were irrigated with
cold buffer. (A) The total number of leuko-
cytes (WBC) in peritoneal lavage fluids of
each mouse was determined microscopically.
(B) The total number of neutrophils in the
peritoneal lavage fluid was calculated after the
percentage of neutrophils was determined
microscopically by Wright’s stain. Data rep-
resent the mean of three experiments.151 Thomas et al.
totic thymocytes (15). It may reflect the inability of 2F8 to
fully mask the binding site(s) for S. aureus in the collagenous
domain of SR-AI/II, and/or the participation of other
scavenger receptors, such as MARCO (39) or CD36 (40),
in phagocytosis of gram-positive bacteria. Regardless of the
reasons for the incomplete inhibition of binding and inges-
tion of gram-positive bacteria by 2F8, it is likely that LTA on
the surface of these bacteria interacts directly with SR-AI/
II (21), and that this interaction is an essential first step in ini-
tiating opsonin-independent phagocytosis of unencapsu-
lated gram-positive bacteria.
Killing of S. aureus (Cowan I) by Neutrophils from MSR-A2/2
and MSR-A1/1 Mice. Approximately equal numbers of neu-
trophils were elicited after intraperitoneal injection of S. aureus
(Cowan I) into the peritoneal cavities of MSR-A2/2 and
MSR-A1/1 mice (Fig. 3 B). However, z12-fold more vi-
able bacteria (4 3 105 vs. 3 3 104) were recovered from
the peritoneal cavity of MSR-A2/2 than MSR-A1/1 mice
(Fig. 1 A). Although neutrophils do not express SR-AI/II
(41), it was possible that genetic disruption of the class A
scavenger receptor impaired in some unknown manner
the ability of neutrophils from MSR-A2/2 mice to phago-
cytose and kill bacteria. To exclude this possibility, we com-
pared killing of S. aureus (Cowan I) by peritoneal exudate
neutrophils from MSR-A2/2 and MSR-A1/1 mice. S. aureus
(Cowan I) bacteria were killed equally by neutrophils from
Figure 4. Phagocytosis of gram-positive bacteria by TMf from MSR-A2/2 and MSR-A1/1
mice. Macrophages were prepared, and phagocytosis was measured as described in Materials and
Methods. (A) Phagocytosis of various fluorescently labeled gram-positive bacteria and of zymosan
particles by TMf from MSR-A2/2 or MSR-A1/1 mice. (B) Phagocytosis of various fluorophore-
labeled live gram-positive bacteria in serum-free buffer, with or without Ca21, Mg21, or LTA, by
TMf from MSR-A1/1 mice. (C) Phagocytosis of S. aureus (Cowan I) by TMf from MSR-A1/1
mice in the absence or presence of various SR-AI/II ligands: polyguanylic acid (polyG, 0.5 mg/
ml), polyinosinic acid (polyI, 0.5 mg/ml), fucoidan (0.5 mg/ml), LTA (1.0 mg/ml), or polycyti-
dylic acid (polyC, 0.5 mg/ml) in the presence of an RNase inhibitor (10 U/ml). (D) Phagocytosis
of various gram-positive bacteria and of zymosan particles by TMf from MSR-A1/1 mice in the
presence of the anti–SR-AI/II antibody 2F8, or an isotype-matched control antibody (EM-34.1).
(E) Phagocytosis of S. aureus (Cowan I) by TMf from MSR-A1/1 mice in the presence of various
concentrations of 2F8 or LTA. All data represent the mean of six to eight experiments.152 Macrophage Scavenger–dependent Phagocytosis in Gram-positive Infection
MSR-A2/2 and MSR-A1/1 mice (Table I). These results are
in agreement with previous findings that macrophages are
the first line of defense against S. aureus infection in the
mouse peritoneal cavity (27, 28).
Ineffective Phagocytosis of an Encapsulated S. aureus Strain
(Smith Diffuse). The data presented thus far indicate that
S. aureus strain Cowan I is phagocytosed by macrophages by
an opsonin-independent mechanism that involves interactions
of ligands on the surfaces of these bacteria, presumably
LTA, with SR-AI/II. They suggest that SR-AI/II–medi-
ated opsonin-independent phagocytosis of S. aureus strain
Cowan I by macrophages in the peritoneum of MSR-A1/1
mice permits these mice to resist intraperitoneal infection
with a dose of this bacterium that is lethal for MSR-A2/2
mice. If this interpretation is correct, then MSR-A2/2 and
MSR-A1/1 mice should be equally susceptible to infection
with an encapsulated S. aureus strain, such as Smith diffuse,
which is not phagocytosed in the absence of opsonins by
TMf from either MSR-A2/2 or MSR-A1/1 mice (Fig. 4
A). Indeed, MSR-A2/2 and MSR-A1/1 mice were equally
susceptible to intraperitoneal challenge with S. aureus Smith
diffuse (Table II), confirming that the increased susceptibil-
ity of MSR-A2/2 mice to infection with S. aureus Cowan I
is related to the inability of macrophages lacking SR-AI/II
to phagocytose S. aureus Cowan I in an opsonin-indepen-
dent manner, and not to other immune defects.
Discussion
The inability of peritoneal macrophages from MSR2/2
mice to phagocytose S. aureus (Cowan I), the impaired abil-
ity of MSR-A2/2 mice to clear S. aureus from their perito-
neal cavities, and the increased susceptibility of MSR2/2
versus MSR1/1 mice to lethal intraperitoneal challenge with
S. aureus provide the first direct evidence that macrophage
SR-AI/II play an essential role in host defense against S. aureus
and other gram-positive microorganisms by promoting op-
sonin-independent phagocytosis of these bacteria.
The majority of S. aureus infections in humans are caused
by microencapsulated or unencapsulated strains similar to the
Cowan I strain used in the present studies (42). Like other
gram-positive bacteria, they express LTA on the surfaces of
their cell walls. LTA interacts directly with SR-AI/II on
mononuclear phagocytes (21), leading to the opsonin-inde-
pendent phagocytosis of these bacteria (Fig. 4, A–E). This may
explain why shortly after intraperitoneal infection a much
larger percentage of S. aureus Cowan I was cleared by resident
peritoneal macrophages of MSR1/1 than of MSR2/2 mice
(Fig. 1).
In humans, introduction of dialysis fluid into the peritoneal
cavity reduces the concentration of antibodies and comple-
ment to a level insufficient to opsonize bacteria for phagocy-
tosis (43). In mice, intraperitoneal inoculation of 1 ml of buf-
fered saline containing S. aureus dilutes enormously the very
small volume of fluid that coats the peritoneal cavity and is
likely to have a similar inhibitory effect on the efficiency of
opsonization. However, the inflammatory response initiated
by peritoneal inoculation of these bacteria promotes the in-
flux of neutrophils, monocytes (Fig. 3), and plasma proteins
(e.g., complement, antibodies). We envision that this led to
opsonization of S. aureus Cowan I and clearance of these bac-
teria from the peritoneum of MSR2/2 mice challenged with
sublethal doses of S. aureus Cowan I (Fig. 1). Similarly, it is
likely that bacteria that entered the bloodstream of sublethally
challenged MSR2/2 mice (Fig. 1) were opsonized by anti-
bodies and complement and were cleared by Fcg- and com-
plement receptor–dependent phagocytosis. This is consistent
with our observation that even in the absence of opsonins,
phagocytosis of gram-positive bacteria by MSR1/1 macro-
phages is somewhat more efficient in the presence of divalent
cations than in their absence (Fig. 4 B). Divalent cations are
required both for the activation of complement, and for
binding of complement-coated bacteria by integrins such as
CD11b/CD18 (complement receptor 3). CD11b/CD18
plays an important role in phagocytosis of other bacterial
pathogens (for a review, see reference 3). We suggest that
these opsonin-dependent mechanisms account for the ability
of MSR2/2 mice challenged intraperitoneally with sublethal
numbers of S. aureus Cowan I to clear these bacteria from the
peritoneum and blood.
As indicated above, LTA on the surface of unencapsu-
lated S. aureus (Cowan I strain) is probably responsible for the
phagocytosis of these bacteria by MSR1/1 macrophages
(Fig. 4). In contrast, capsular polysaccharides mask the LTA
of Smith strain S. aureus (44, 45). These capsular polysac-
charides are not ligands for SR-AI/II on mononuclear phago-
cytes. Presumably this is the reason why the encapsulated
Table I. Killing of S. aureus (Cowan I) by Peritoneal Exudate 
Neutrophils from MSR-A2/2 and MSR-A1/1 Mice
PMN/S. aureus ratio MSR-A1/1 MSR-A2/2
%%
6:1 55 6 7 51 6 6
Killing of S. aureus (Cowan I) by neutrophils was determined in a tumble
assay as described in Materials and Methods. Data represent mean
percent killing 6 SEM for three experiments.
Table II. Mortality of MSR-A1/1 and MSR-A2/2 Mice after 
Injection with Encapsulated S. aureus
S. aureus (Smith diffuse) MSR-A1/1 MSR-A2/2
CFU/mouse
5 3 107 6/8 (75%) 7/8 (87.5%)
5 3 108 8/8 (100%) 7/8 (87.5%)
MSR-A1/1 and MSR-A2/2 mice were infected intraperitoneally by
injection of S. aureus Smith diffuse (5 3 107 and 5 3 108 CFU). Mice were
observed for signs of systemic infections, and sick animals were killed. Data
are presented as number of dead mice per total number of mice.153 Thomas et al.
Smith strain of S. aureus was not phagocytosed in the absence
of opsonins by MSR1/1 macrophages (Fig. 4 A).
Virtually all adult humans express antibodies to S. aureus
cell wall constituents. However, antibodies against S. aureus
cell wall constituents do not promote phagocytosis of en-
capsulated S. aureus strains by neutrophils and monocytes.
This is because the capsular polysaccharides of S. aureus mask
antibodies and complement deposited on the S. aureus cell
wall (45–47), thereby preventing the interaction of these
opsonins with Fc and complement receptors on neutrophils
and mononuclear phagocytes. This is probably the reason
why the LD50 of the encapsulated Smith strain of S. aureus is
substantially lower than that of the unencapsulated Cowan I
strain, and why MSR2/2 and MSR1/1 mice were equally
susceptible to lethal infection with the encapsulated Smith
strain. The report by Karakawa et al. (48) that specific anti-
capsular antibodies are required to promote phagocytosis of
encapsulated S. aureus, and Cohn’s (29) observation that anti-
bodies directed against the capsular polysaccharides of Smith
strain S. aureus protect against intraperitoneal challenge with
this bacterium are consistent with this interpretation.
Staphylococcal species from the normal skin flora are the
most frequent causative agents of bacterial peritonitis (49), a
significant cause of morbidity and mortality in patients un-
dergoing peritoneal dialysis (50). Carrozi and colleagues (51,
52) have shown that intraperitoneal administration of IgG
reduces the incidence of bacterial peritonitis in some but
not all peritoneal dialysis patients. Peritoneal macrophages
of dialysis patients unresponsive to intraperitoneal IgG ad-
ministration exhibited deficient Fc receptor activity, and this
deficit was partially reversed by IFN-g administration (53).
The findings presented here suggest that cytokines such as
M-CSF (54) or pharmacologic agents that increase SR-AI/II
expression on mononuclear phagocytes may help reduce the
incidence of bacterial peritonitis, especially with unencap-
sulated gram-positive bacteria, in peritoneal dialysis patients.
MSR2/2 mice are more susceptible to lethal infection
with S. aureus (Cowan I) (Fig. 2), L. monocytogenes, HSV-1
(22), and to the lethal effects of LPS (23) than MSR1/1 mice.
Our observations suggest that SR-AI/II exert their protec-
tive effect against S. aureus infection by promoting the clear-
ance of these bacteria by macrophages (Figs. 1 and 4). SR-AI/
II may also protect against the lethal effects of LPS by pro-
moting endocytosis of LPS, which would minimize LPS–
CD14 interaction and thereby diminish synthesis and secre-
tion of TNF-a. However, L. monocytogenes and HSV-1 are
intracellular pathogens, and neither organism requires SR-AI/
II to enter or grow within host cells. Thus, increased up-
take of L. monocytogenes or HSV-1 does not explain the ben-
eficial effect of macrophage SR-AI/II in host defense against
infections with these intracellular pathogens.
SR-AI/II mediate phagocytosis of apoptotic thymocytes
(15). Phagocytosis of apoptotic Mycobacterium avium–infected
macrophages by fresh uninfected macrophages leads to the
killing of M. avium contained within the apoptotic macro-
phages (55). It is possible that SR-AI/II play a similar role
in clearing apoptotic Listeria- or HSV-1–infected cells. Two
findings are consistent with this suggestion. First, both List-
eria (56) and HSV-1 (57) induce apoptosis of the cells they
infect. Second, mice whose monocytes have been inhibited
by antibodies that block CR3 (CD11b/CD18 [58]) or whose
macrophages have been depleted die when infected with
doses of HSV-1 (59) or L. monocytogenes (60) that are toler-
ated by normal mice. We suggest that SR-AI/II participate
in controlling infections with these intracellular pathogens by
promoting the phagocytosis and subsequent degradation of
infected apoptotic cells and the pathogens they contain.
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